NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two cardiovascular indications
HONG KONG, June 1, 2023 /PRNewswire/ -- Akeso Inc. (9926. HK, "Akeso") announced today that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications 1) primary hypercholesterolemia and mixed hyperlipidemia, and 2) heterozygous familial hypercholesterolemia (HeFH). Ebronucimab is jointly developed by Akeso and AD Pharmaceuticals (a joint venture with Akeso).
The new drug marketing application for ebronucimab is based on four pivotal phase 3 studies, including three pivotal studies in patients with primary hypercholesterolemia and mixed hyperlipidemia and one pivotal study in patients with HeFH.
Findings from the clinical results:
For efficacy
All three dosing regimens were confirmed to be effective with statistical and clinical significance after 12-week treatment for both primary hypercholesterolemia & mixed hyperlipidemia, and heterozygous familial hypercholesterolemia (HeFH). The lipid-lowering efficacy in both indications was maintained over a 52-week long-term treatment, demonstrating the ability of ebronucimab to deliver a consistent and lasting benefit to patients.
The efficacy results of ebronucimab were consistent across studies and across different indication populations. Treatment with all three dosing regimens of ebronucimab can achieve significant reductions in LDL-C levels from baseline, with a maximum reduction of more than 65% in each dosing cycle.
Among the three dosing regimens, Q6W dosing (every 6 weeks) enables longer dosing intervals, is expected to enhance clinical adherence, and provides patients with more efficient, convenient, and flexible treatment options, thus contributing to personalized treatment.
Treatment with ebronucimab can also significantly lower TC, non-HDL-C and ApoB levels, and increased HDL-C and ApoA-I levels. By promoting a more favorable lipid profile, long-term stable treatment with ebronucimab is expected to achieve greater cardiovascular benefit.
For safety
Ebronucimab has an advantageous safety profile. No significant differences in safety outcomes were observed in aged population.
PCSK9 is known to be the most effective lipid-lowering target after statins. Authoritative organizations have estimated that the market for PCSK9 in China will grow at a 36.9% CAGR from 2023 to 2030.
Based on the remarkable efficacy and safety profile in primary hypercholesterolemia (including HeFH) and mixed hyperlipidemia, it is anticipated that ebronucimab will provide a new generation of lipid-lowering drugs with improved efficiency and safety for patients.
Marc Dubrick and Lisa Becharas are bringing victories home to Boulder, Colorado, after winning their first St. Anthony's Triathlon along St. Petersburg's scenic downtown waterfront. The winners, who are teammates on The Real Triathlon Squad, raced a...
Nicholas Baker, M.D., Director of Robotic Thoracic Surgery at the University of Pittsburgh Medical Center (UPMC) Passavant, presented key findings from independent research at the 104th Annual Meeting of the American Association for Thoracic Surgery...
Sexton Lawn & Landscapes is thrilled to announce the appointment of Brooks Breland as the leading Lawn and Plant Health Expert. In this role, Breland will...
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9...
SightMD Pennsylvania, a leading multi-specialty ophthalmology platform, is pleased to announce the acquisition of James Lewis, MD. Through this strategic partnership, Dr. Lewis's practice at 8380 Old York Rd Ste 110, Elkins Park, PA 19027 will expand...
" Catholic school boards and their dedicated staff work tirelessly in support of the mental, physical, intellectual, and spiritual well-being of students in Catholic schools," said Patrick Daly, President of the Ontario Catholic School Trustees'...